Timothy Sangiovanni - Kempharm President

KMPH -  USA Stock  

USD 10.99  0.23  2.14%

  President
Mr. Timothy J. Sangiovanni serves as Vice President, Corporationrationrate Controller of the Company. Previously, Mr. Sangiovanni served as our director of financial reporting since August 2015. Prior to joining our company, Mr. Sangiovanni served as manager of internal audit worldwide, with Tupperware Brands Corporationrationration, a publiclyheld marketer of home and personal care products from April 2013 to August 2015. From January 2007 to March 2013, Mr. Sangiovanni served in a variety of roles with KPMG, LLP, including audit associate, senior audit associate and audit manager. Mr. Sangiovanni was a billing analyst with Switch and Data Facilities, Inc. from October 2005 to December 2006
Age: 34  President Since 2017      
321 939 3416  http://kempharm.com
Sangiovanni received his B.A. in Accounting from the University of South Florida and is a certified public accountant in the state of Florida.

Timothy Sangiovanni Latest Insider Activity

Tracking and analyzing the buying and selling activities of Timothy Sangiovanni against Kempharm stock is an integral part of due diligence when investing in Kempharm. Timothy Sangiovanni insider activity provides valuable insight into whether Kempharm is net buyers or sellers over its current business cycle. Note, Kempharm insiders must abide by specific rules, including filing SEC forms every time they buy or sell Kempharm'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Kempharm Management Efficiency

Kempharm has return on total asset (ROA) of 6.45 % which means that it generated profit of $6.45 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of (222.16) %, meaning that it created substantial loss on money invested by shareholders. Kempharm management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Average Equity is estimated to increase to 0.20, while Return on Average Assets are projected to decrease to (1.26) . Kempharm Assets Non Current are most likely to increase significantly in the upcoming years. The last year's value of Assets Non Current was reported at 2.83 Million. The current Asset Turnover is estimated to increase to 1.26, while Return on Average Assets are projected to decrease to (1.26) .
The company currently holds 2.75 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Kempharm has a current ratio of 20.29, suggesting that it is liquid enough and is able to pay its financial obligations when due.
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Similar Executives

Found 4 records

PRESIDENT Since

Ryan SpencerDynavax Technologies
2019
Michael OstrachDynavax Technologies
2016
Robert JanssenDynavax Technologies
2018
David JohnsonDynavax Technologies
2014
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people. Kempharm (KMPH) is traded on NASDAQ Exchange in USA. It is located in 1180 Celebration Boulevard and employs 22 people. Kempharm was previously known as Kempharm and was traded on NASDAQ Exchange under the symbol KMPHD. Kempharm is listed under Pharmaceutical Products category by Fama And French industry classification.

Kempharm Leadership Team

Elected by the shareholders, the Kempharm's board of directors comprises two types of representatives: Kempharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kempharm. The board's role is to monitor Kempharm's management team and ensure that shareholders' interests are well served. Kempharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kempharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
David Tierney, Independent Director
Sven Guenther, Executive Vice President -Research and Development
LaDuane Clifton, CFO
Joseph Saluri, Independent Director
Travis Mickle, Founder, Chairman, CEO and President and Member of Scientific and Medical Advisory Board
Timothy Sangiovanni, Principal Accounting Officer, Vice President Corporate Controller
Matthew Plooster, Independent Director
Gordon Johnson, Chief Bus. Officer
Richard Pascoe, Lead Independent Director
Danny Thompson, Independent Director

Kempharm Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kempharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Kempharm without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Global Markets Map Now

   

Global Markets Map

Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kempharm using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Stocks Correlation. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Piotroski F Score module to get Piotroski F Score based on binary analysis strategy of nine different fundamentals.

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.